drugset / Trial / NCT00985504

A Study of Patients With Major Depressive Disorder and Residual Apathy

NCT00985504

Phase 4 Completed 483 enrolled Eli Lilly and Company Boehringer Ingelheim · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to provide a comparison of the apathy, depression, and functional outcomes associated with switching to duloxetine or escitalopram in patients who have previously responded to treatment with a selective serotonin reuptake inhibitor (SSRI) for major depressive disorder and who have residual apathy in the absence of depressed mood.

Timeline

Start
2009-09
Primary completion
2010-12
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Duloxetine Small molecule 60 mg Oral
Subject Duloxetine Small molecule 120 mg Oral
Comparator Escitalopram Small molecule 10 mg Oral
Comparator Escitalopram Small molecule 20 mg Oral